Virpax Pharmaceuticals VRPX Investor Presentation August 2023

Virpax Pharmaceuticals is developing differentiated non-addictive treatment options in pain management and related multi-billion-dollar markets through collaborations with the NIH and Department of Defense. The company's lead candidate, Probudur, targets postoperative pain management, with two additional pain assets anticipated to enter human trials in 2024.